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Abstract: Benign lymphoepithelial cysts are a widely recognized cause of parotid gland 
swelling in patients infected with the human immunodeficiency virus (HIV). These cysts are 
  pathognomonic for HIV . The cysts frequently grow to be exceptionally large, causing   physical 
deformity and gross asymmetry of facial contour. This clinical commentary analyzes this 
cosmetically deforming disease entity and the many treatments that accompany it. The patient 
presented in this paper is a surgical case-control. The case is a microcosm for our findings upon 
review of the literature. Treatment options for benign lymphoepithelial cysts include repeated 
fine-needle aspiration and drainage, surgery, radiotherapy, sclerotherapy, and conservative 
therapy, with institution of highly active antiretroviral therapy medication. Based on this   surgical 
case-control and our review of the literature, it is concluded that surgical intervention offers the 
best cosmetic result for these patients.
Keywords: parotid, benign lymphoepithelial cyst, parotidectomy, human immunodeficiency 
virus, head and neck surgery, cosmetic surgery
Introduction
A 32-year-old female with human immunodeficiency virus (HIV) infection presented 
to our office six years after we had performed a right superficial parotidectomy for a 
10 cm × 8 cm benign lymphoepithelial cyst (BLEC). This was cured surgically with 
excellent cosmetic outcome. The patient presented at this time with a similarly large 
lesion on the contralateral side which was removed in a similar fashion (see Figure 1). 
The patient tolerated the procedure well with no postoperative morbidity, normal facial 
nerve function, and a well healed scar.
The 6-year follow-up on this patient represents a case control study   demonstrating 
the efficacy of parotidectomy in the treatment of BLEC. The only indication for 
removal of BLEC is when there is an expanding lesion distorting the patient’s facial 
appearance. In order to delve further into the best treatment for this cosmetic problem, 
a Medline search and review of the literature on BLEC was performed. To the best of 
the authors’ knowledge, this paper is the first to review the etiology, diagnosis, and 
treatment options for BLEC.
Literature review
Benign lymphoepithelial cysts (BLECs) are a widely recognized cause of parotid 
gland swelling in HIV-infected patients. Although they are neither invasive nor 
associated with malignant degeneration, BLECs can become large and disfiguring. 
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These lesions can be a cosmetically devastating physical 
deformity, causing isolation and depression.1–6 They are 
easily recognized as a manifestation of HIV in the aware 
population.
BLEC of the parotid gland is the most common salivary 
gland pathology in HIV .1,2 BLEC has two hypothesized 
etiologic mechanisms. The first theorized pathogenesis 
of BLEC is the “obstructive theory” which states that 
lymphoid proliferation in the parotid gland leads to ductal 
  obstruction and salivary dilation that mimics a true cyst.1,3,4,7–9 
The second hypothesized theory is that HIV-related   reactive 
lymphoproliferation occurs in the lymph nodes of the parotid 
gland. The parotid glandular epithelium becomes trapped 
in normal intraparotid lymph nodes, resulting in cystic 
enlargement.1,7,8
Diagnosis of BLEC is made based on history,   physical 
examination, and fine-needle aspiration biopsy. BLEC is 
nearly diagnostic for HIV .1,2 Physical examination will 
show obvious fluctuant cystic facial deformity. Fine-needle 
aspiration biopsy of BLEC results in clear, proteinaceous 
(straw-colored) fluid, with a mixture of epithelial (squamous) 
and benign lymphoid cells.7,10 This combination of history, 
physical examination, and fine-needle aspiration biopsy is 
diagnostic for BLEC.3,10
Treatment of this particular pathology has been widely 
debated in the literature. Previous treatments for BLEC 
have included repeated fine-needle aspiration and drain-
age, surgery, radiotherapy, sclerotherapy, and conservative 
therapy with institution of highly active antiretroviral 
therapy (HAART) medications.2–6,10–22 Table 1 summarizes 
the advantages and disadvantages, duration of procedures, 
Figure 1 Patient with HIV BLEC of the left parotid gland. 
Notes: Patient is status postsuperficial parotidectomy on the right side 6 years ago 
(complete resolution). Patient routinely wears multiple accessories daily to distract 
others from her obvious facial lesion (32-year-old patient, May 2010).
Abbreviation: BLEC, benign lymphoepithelial cyst.
Table 1 Advantages and disadvantages of treatment for benign lymphoepithelial cysts of the parotid gland as well as treatment duration 
and cost of treatment
  Advantages Disadvantages Length of  
treatment
Estimated cost of  
treatment
HAART therapy •  Noninvasive
•  Standard of care for HIV
•  Partial response
•  Incomplete response $3 months $1250/month
FNA drainage •  Minimally invasive
•  Avoids radiation
•  100% recurrence rate
•  Multiple treatments
#2×/month $450/procedure
Radiation therapy •  Noninvasive
•  Avoids needle stick injuries
•  Therapeutic doses of radiation (24 Gray)
•    Side effects include xerostomia,  
skin necrosis, mucositis
•  Incomplete response
3 weeks $17,600 total
Sclerotherapy •  Minimally invasive
•  Avoids radiation
•  Multiple treatments 
•    Varying degrees of drug toxicities ranging  
from rash to pulmonary fibrosis
•  Incomplete response
•  Fibrosis makes future surgery more difficult
1–4 procedures $450/procedure
Bleomycin, $1450/
procedure
OK-432, orphan drug, 
not approved by the 
FDA in the US
Surgery •  Complete response
•  Cosmetically superior
•  Avoids radiation
•  General anesthesia
•  23-hour observational stay in hospital
•  2–6-hour invasive procedure
•  Surgical scar
•    Surgical complications hematoma (7%),  
facial nerve injury (2.3%–6%), Frey’s  
syndrome (5%), recurrence (2%)15,16,26,27
One surgery $8000 total
Abbreviations: FNA, fine-needle aspiration; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus.
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and the cost of treatment for BLEC. A literature review of 
the aforementioned treatments for BLEC is summarized in 
the remainder of this paper and in Table 2.
HAART
Instituting HAART for BLEC has been shown to be effec-
tive in decreasing the size of the lesions.2,7 HAART treats 
systemic HIV by inhibiting retroviral transcription and 
viral replication. HAART therapy is theorized to correct 
the root cause of BLEC, ie, HIV infection. In a study by 
Syebele and Bütow, nine of ten patients with BLEC were 
found to have “a significant decrease in cyst size” (which 
was not quantified) after institution of HAART.2 Cysts were 
still present at completion of the study. medications insti-
tuted in the study included two nucleoside analog reverse 
transcriptase inhibitors (stavudine and lamivudine) and one 
non-  nucleoside reverse transcriptase inhibitor (efavirenz).2
Fine-needle aspiration and drainage
Repeated fine-needle aspiration and drainage is a popular 
treatment for BLEC. The first aspiration typically occurs in 
the setting of the fine-needle aspiration biopsy, which rules 
out the possibility of another pathologic condition. Cysts 
can be drained up to twice per month, but there is a 100% 
recurrence rate in spite of this treatment.15,16,20
Radiation therapy
In 1995, 12 patients with BLEC were given 8–10 Gray of 
radiation therapy. Although initial results were encourag-
ing, longer follow-up revealed that only one of 12 patients 
had adequate cosmetic control at 9.5 months.18 Worse, after 
initial failure, retreatment of eight patients with 8–10 Gray 
produced fewer responses and no long-term local control.18 
In 1999, Beitler et al studied 20 patients with BLEC, each 
treated with 18–24 Gray of radiation therapy to the parotid 
glands.3 They were able to demonstrate partial cosmetic 
control of the disease in 14 of 20 patients. Side effects of 
treatment included xerostomia and mucositis.3
Sclerotherapy
Sclerotherapy injections for BLEC includes multiple sclerotic 
agents, eg, sodium morrhuate, doxycycline, ethanol,   bleomycin, 
and OK-432.4,6,12,13,21 The studies on ethanol only evaluated 
patients subjectively as being pleased or displeased with their 
results, and therefore will not be   discussed.12   Doxycycline 
injection into the cysts resulted in a 22% (2/9 cysts) complete 
response rate.22 Two of the patients in the doxycycline treat-
ment group opted for superficial   parotidectomy as definitive 
treatment for their cysts.13 In two studies evaluating sodium 
morrhuate   sclerotherapy, injections resulted in 17% (1/6 
cysts) and 44% (4/9)   complete response rates, respectively.4,9 
Although limited in patient population size, sclerotherapy with 
bleomycin resulted in completed resolution in 3/3 patients 
(100%) with no side effects (although it has been noted to 
cause life-threatening irreversible pulmonary fibrosis when 
given as chemotherapy).6 OK-432 (picibanil) has been strongly 
advocated as the treatment of choice for macrocystic lymphatic 
malformations.23 Although BLEC is a different pathologic 
entity from cystic hygroma, there has been one reported 
case of BLEC that was satisfactorily treated with OK-432. 
Heran and Legiehn reported on multiple injections of OK-432 
performed in one patient over the course of three months. The 
patient initially had the common side effects of low-grade fever 
and local swelling/erythema at the injection site, but these 
were self-limiting and resolved after one month. At one-year 
follow-up, the patient had no significant clinical recurrence.21 
Of note, this study was not published in a peer-reviewed jour-
nal, but was presented in its entirety at the 2009 meeting of 
the Cardiovascular and Interventional Radiological Society of 
Europe in Lisbon, Portugal.21
Surgery
The initial studies regarding BLEC and surgery were per-
formed in the early 1990s. Shaha et al undertook a retrospective 
review of 35 parotidectomies (20 superficial parotidectomies, 
15 removal of the parotid tail for isolated cysts) for BLEC with 
up to six years of follow-up.15 A complete response was seen 
in all 35 patients, although cysts did develop on the contral-
ateral side in several patients. A study by Ferraro et al looked 
at surgical enucleation of 10 patients with bilateral BLEC (20 
Figure 2 Patient 6 weeks postoperatively after left superficial parotidectomy. A 
similar result can be seen as compared to the right side. Facial contour and symmetry 
has been restored with excellent cosmetic outcome.
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cysts total). Follow-up ranged from 3 to 36 months, with 19 
complete responses and one recurrence.16
Discussion
The indication for treatment of BLEC is cosmetic. As stated 
earlier, this pathology can be a cosmetically devastating 
physical deformity, causing social isolation and depres-
sion.1–6 The treatment that provides the best cosmetic out-
come should be the treatment of choice. All treatments for 
BLEC show a partial response, but the only treatment to 
show a complete response in this pathology consistently with 
no recurrence is surgical intervention. Although bleomycin 
and OK-432 sclerotherapy injections have shown promis-
ing results, the data are currently limited to a case series 
(bleomycin, three patients) and a case report (OK-432). 
Limited data on the aforementioned therapies are available 
because these pilot studies were only recently performed. 
There is a need for further clinical data to support the use 
of bleomycin and OK-432 sclerosants in the treatment of 
BLEC. The side effect profile of OK-432 is mostly inflam-
matory in nature, with the major side effect being airway 
obstruction in patients treated for lymphatic malformations.23 
Fatal side effects have been associated with bleomycin in 
the form of irreversible pulmonary fibrosis.23 In addition, 
the majority of BLECs are multiloculated, making injec-
tions into each loculation on multiple occasions challenging, 
time-consuming, and often unsuccessful. In 2009, Smith 
et al reported no response to treatment with OK-432 in 17 
cases of microcystic multiloculated lymphatic malforma-
tions.23 The last potential pitfall of sclerotherapy is that 
these agents aim to scar the particular area of injection to 
cause obliteration. If sclerotherapy is unsuccessful, then 
surgical intervention for cure is more difficult in the setting 
of scarring and sclerosis. The doxycycline study by Lustig 
et al17 shows how failures of sclerotherapy must resort to 
surgical intervention for definitive treatment (2 patients). 
The scarring caused by sclerotherapy could cause more 
postsurgical morbidity in the setting of a scarred operative 
field (eg, facial nerve injury).
Reservations regarding parotidectomy in HIV-infected 
patients include the following: immunocompromised patients 
have a higher rate of postoperative infections, there is an 
unnecessary risk of HIV transmission imposed on the surgeon 
and the surgical team, and there could be facial nerve injury. 
Recent studies show that the postoperative rate of infection in 
HIV-infected patients is similar to that in the normal popula-
tion, and is likely due to advances in the treatment of this 
disease.24 New drug regimens for the medical treatment of 
HIV patients in the perioperative period have been developed, 
and with the advent of viral load measurement, the risks of 
HIV transmission during surgery have been dramatically 
reduced.25 Regarding the complications of parotidectomy in 
the treatment of BLEC, surgical intervention has been com-
pared with routine superficial parotidectomy for pleomorphic 
adenoma.26 In the hands of an experienced surgeon, parotid 
gland surgery for benign disease has been shown to have a 
permanent paresis rate of 2.3% (one or more branches of the 
facial nerve), while partial superficial parotidectomy has a 
permanent paresis rate of 0% (Table 2).26,27
There are two other issues that must be addressed 
regarding surgical intervention. The prognosis of HIV has 
changed markedly in the past 30 years. From 1981 to 1996, 
the disease had a dismal prognosis, but since the establish-
ment of HAART therapy in 1996, HIV has become a chronic 
disease with an excellent prognosis.28 Given the success of 
surgery in BLEC, the argument for surgical intervention is 
further strengthened by the improved health and longev-
ity of HIV-infected patients. The second issue regarding 
surgical intervention is that some surgeons believe that the 
surgical defect caused by removal of these large cysts will 
cause a substantial cosmetically deforming indentation. 
  Parotidectomy defects can be cosmetically reconstructed in 
a variety of ways, including use of a cadaveric dermal matrix 
  (Alloderm®), abdominal fat grafts, sternocleidomastoid 
muscle flaps, de-epithelialized radial forearm free flaps, and 
rectus abdominus free flaps.29 In the case presented here, a 
cervical rotation flap with placement of Alloderm was per-
formed to correct the patient’s left-sided parotid defect. In 
order to avoid donor site morbidity, the authors decided that 
Alloderm was the best reconstructive option for this patient. 
At 6 weeks postoperatively, the patient was doing well, with 
excellent facial symmetry (Figure 2).
The case presented here illustrates excellent postsurgical 
control of BLEC after 6 years and demonstrates the disease 
course of untreated progression on the contralateral side. This 
patient represents an unblinded surgical case-control which 
demonstrates the efficacy of surgery for this condition.
Conclusion
There are many suboptimal cosmetic therapies used in the 
treatment of BLEC. Surgery is the gold standard treatment 
for BLEC, as evidenced by this literature review and case 
example.
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